InvestorsHub Logo
Followers 6
Posts 5991
Boards Moderated 0
Alias Born 06/27/2018

Re: None

Wednesday, 06/28/2023 6:09:58 PM

Wednesday, June 28, 2023 6:09:58 PM

Post# of 1530
Loxxx, I will mention that this next reverse merger is what Teper alone created by forming Cytovia Tx and Immune previous. It will be interesting to them merge. Obviously Epicept was a completely different entity unto itself that I don’t believe Teper played a role in. This new reverse triangular merger etc is all on him and his creation. Not tying to give him and kudos, I’m just pointing out that it is a different set up and maybe there will be some slight variation in timing and arrangement. I just know all has to be completed by February. I’m hoping with fingers crossed that they do something similar as they did in 2013, but that’s just me hoping and wishing. I for one would like to watch them do the multiple financing and step the price up from hopefully a low ball listing. I also would like to watch a remnant sale happen in Fall. I wish I could see reorganization filings from 2013/2014. Sadly all that info is non-existence. That’s life for you. At this stage I remain a fool flying blind. I’m pretty sure Cellectis will default, can’t see anything completed purely based on the fact that bankruptcy isn’t completed and distribution still needs to be settled and final order finished etc. Plus, Trustee still needs to settle with debtors lawyers blah blah blah. I find it interesting that the Trustee hasn’t mentioned remnant sale but maybe that will be brought up soon enough. Who really knows. I sure don’t. I’ve never gone through a bankruptcy before. All new to me. Fun times. I’m just glad to come for the ride with all those brilliant creditors and banker swindler type folk. It’s been a pleasure being trolled. Be well. Cuckoo Penny

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.